Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications Agilent Technologies Inc. (NYSE: A) today ...

Canadian researchers have developed an effective new technique for identifying aggressive medulloblastoma—the most common ...

When used in conjunction with the PD-L1 IHC 28-8 pharmDx as a companion test, in the European Union: (a) resectable NSCLC patients with PD-L1 expression ≥1% and at high risk of recurrence may be ...

Technologies announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...

Canadian researchers have developed an effective new technique for identifying aggressive medulloblastoma-the most common type of malignant brain ...

Canadian researchers have developed an effective new technique for identifying aggressive medulloblastoma—the most common type of malignant brain tumour in children—and potentially sparing young ...

Pakistan Tehreek-e-Insaf (PTI) founding chairman Imran Khan has filed a petition in Pakistan’s Supreme Court, challenging the ...

NeoGenomics announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey.

Canadian researchers have developed an effective new technique for identifying aggressive medulloblastoma-the most common type of malignant brain tumour in children-and potentially sparing young ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.